Company Filing History:
Years Active: 2021
Title: Katja Wosikowski-Buters: Innovator in Ophthalmic Treatments
Introduction
Katja Wosikowski-Buters is a prominent inventor based in Munich, Germany. She has made significant contributions to the field of ophthalmology through her innovative research and development of therapeutic solutions. Her work focuses on addressing critical issues related to ophthalmic diseases.
Latest Patents
Katja holds a patent for a TGF-beta oligonucleotide designed for use in the treatment of ophthalmic diseases. The invention is directed to an oligonucleotide comprising a nucleic acid sequence of SEQ ID No. 1 or parts thereof. This oligonucleotide features modifications at the 3'-end and/or 5'-end, which enhance its efficacy in reducing or inhibiting scarring, fibrotic closure of the trabeculectomy canal, and epithelial-to-mesenchymal transition of the trabecular meshwork. Additionally, it provides protective activity for the optic nerve, including the optic nerve head. The patent also includes a pharmaceutical composition that comprises this oligonucleotide and a pharmaceutically acceptable carrier.
Career Highlights
Katja is currently associated with Isarna Therapeutics GmbH, where she continues to advance her research in ophthalmic treatments. Her dedication to innovation has positioned her as a key figure in her field.
Collaborations
Throughout her career, Katja has collaborated with notable professionals, including Eugen Leo and Michel Janicot. These partnerships have further enriched her research and development efforts.
Conclusion
Katja Wosikowski-Buters exemplifies the spirit of innovation in the medical field, particularly in ophthalmology. Her contributions through her patent and collaborations highlight her commitment to improving treatment options for patients with ophthalmic diseases.